1. Home
  2. Directory
  3. Pennsylvania
  4. Philadelphia
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1235637653

ALLISON RAGO BARRETT CRNP
Prescription History 1235637653
Nurse Practitioner - Family in Philadelphia, PA


Quality Rating: 85.48 out of 100 score

NPI Status: Active since January 31, 2018

Contact Information

3400 CIVIC CENTER BLVD
3 WEST
PHILADELPHIA, PA
ZIP 19104
Phone: (215) 615-5858
Fax: (215) 615-3349

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ALLISON RAGO BARRETT CRNP, an active Family specialist practicing in Philadelphia, PA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 80 documented patient claims. Among these therapy options, the most frequently utilized medication is Imbruvica, which accounts for 22 claims alone.

Medication Index

A
C
G
I
M
No matching medications currently found on file.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 20.0
Days Supply 600
PA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills40.8
Peer Average Days Supply1,152
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.51

State Avg Cost Per Claim

$26.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 485
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply660
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $252,667.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,862.77

State Avg Cost Per Claim

$14,167.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Gabapentin

Generic Formulation: GabapentinSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
PA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills141.8
Peer Average Days Supply4,057
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.5% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $162.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.16

State Avg Cost Per Claim

$21.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 646
PA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.8
Peer Average Days Supply904
Conservative Utilization

This provider writes prescriptions for this formulation 29.0% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $514,409.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$23,382.24

State Avg Cost Per Claim

$14,546.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Megestrol Acetate

Generic Formulation: Megestrol AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
PA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills19.8
Peer Average Days Supply509
Conservative Utilization

This provider writes prescriptions for this formulation 35.3% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $192.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.51

State Avg Cost Per Claim

$63.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Therapeutic Applications

Megestrol is used to treat loss of appetite and weight loss in people with AIDS. Improving your appetite and gaining weight may help you feel better and be more active. Megestrol is similar to a natural substance made by the body called progesterone.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ALLISON RAGO BARRETT CRNP provides transparency into local medical care patterns within Philadelphia, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.